Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections
- PMID: 7524797
Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections
Abstract
Intra-abdominal infections are a serious problem for surgeons. Treatment consists of a combination of operation, antimicrobial treatment, and supportive measures. beta-Lactam antibiotics have a major role in the treatment of peritonitis, and in combination with beta-lactamase inhibitors, the penicillins have an even larger part to play than previously. A multicentre prospective trial to evaluate the efficacy and safety of piperacillin/tazobactam in the treatment of serious intra-abdominal infections was conducted in Europe. One hundred and six evaluable patients with documented intra-abdominal infections were treated with piperacillin 4 g/tazobactam 500 mg every eight hours. The most common diagnoses were peritonitis, intra-abdominal abscess, and complicated diverticulitis. A 90% favourable clinical response rate (cured/improved) was found during the first two weeks of treatment. Piperacillin/tazobactam was extremely active against the Gram-negative aerobic, Gram-positive aerobic, and anaerobic bacteria isolated in this trial. Overall, the drug was well tolerated and the side effects were minimal.
Similar articles
-
Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.Eur J Surg Suppl. 1994;(573):61-6. Eur J Surg Suppl. 1994. PMID: 7524798 Clinical Trial.
-
Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections.Eur J Surg. 1999 Sep;165(9):875-84. doi: 10.1080/11024159950189393. Eur J Surg. 1999. PMID: 10533765 Clinical Trial.
-
Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.Eur J Surg Suppl. 1994;(573):51-5. Eur J Surg Suppl. 1994. PMID: 7524796 Review.
-
Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.Am Surg. 1993 Sep;59(9):598-605. Am Surg. 1993. PMID: 8396374 Clinical Trial.
-
Anaerobes in polymicrobial surgical infections: incidence, pathogenicity, and antimicrobial resistance.Eur J Surg Suppl. 1994;(573):31-7. Eur J Surg Suppl. 1994. PMID: 7524793 Review.
Cited by
-
Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.Drugs. 1999 May;57(5):805-43. doi: 10.2165/00003495-199957050-00017. Drugs. 1999. PMID: 10353303 Review.
-
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.Pharmacoeconomics. 2001;19(11):1135-75. doi: 10.2165/00019053-200119110-00006. Pharmacoeconomics. 2001. PMID: 11735679 Review.
-
Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults.Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD004539. doi: 10.1002/14651858.CD004539.pub2. Cochrane Database Syst Rev. 2005. PMID: 15846719 Free PMC article.
-
Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.Ann Surg. 2000 Aug;232(2):254-62. doi: 10.1097/00000658-200008000-00016. Ann Surg. 2000. PMID: 10903605 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical